Header Logo

John Zajecka

TitleProfessor
InstitutionRush University, Rush Medical College
DepartmentPsychiatry
Address
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    My Scopus ID is 57190071825.
    My NIH COMMONS name is JZAJECKA.

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Wallner MA, Eloge JC, Mackey IV, Zajecka J. Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series. J Clin Psychiatry. 2023 02 01; 84(2). PMID: 36724112.
      Citations:    
    2. Kraus C, Quach D, Sholtes DM, Kavakbasi E, De Zwaef R, Dibu? M, Zajecka J, Baune BT. Setting Up a Successful Vagus Nerve Stimulation Service for Patients With Difficult-to-Treat Depression. Neuromodulation. 2022 Apr; 25(3):316-326. PMID: 35123881.
      Citations:    
    3. DeRubeis RJ, Zajecka J, Shelton RC, Amsterdam JD, Fawcett J, Xu C, Young PR, Gallop R, Hollon SD. Prevention of Recurrence After Recovery From a Major Depressive Episode With Antidepressant Medication Alone or in Combination With Cognitive Behavioral Therapy: Phase 2 of a 2-Phase Randomized Clinical Trial. JAMA Psychiatry. 2020 03 01; 77(3):237-245. PMID: 31799993.
      Citations:    
    4. Fava M, Mazzone E, Freeman M, Flynn M, Judge H, Hoeppner B, Hock RS, Shui A, Macaluso M, Morrison MF, Carpenter LL, Shelton R, Zajecka J, Papakostas GI. Double-blind, placebo-controlled, proof-of-concept trial of a kappa-selective opioid receptor antagonist augmentation in treatment-resistant depression. Ann Clin Psychiatry. 2020 02; 32(4):18-26. PMID: 33125454.
      Citations:    
    5. Daly EJ, Trivedi MH, Janik A, Li H, Zhang Y, Li X, Lane R, Lim P, Duca AR, Hough D, Thase ME, Zajecka J, Winokur A, Divacka I, Fagiolini A, Cubala WJ, Bitter I, Blier P, Shelton RC, Molero P, Manji H, Drevets WC, Singh JB. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2019 09 01; 76(9):893-903. PMID: 31166571.
      Citations:    
    6. Zajecka JM, Stanford AD, Memisoglu A, Martin WF, Pathak S. Buprenorphine/samidorphan combination for the adjunctive treatment of major depressive disorder: results of a phase III clinical trial (FORWARD-3). Neuropsychiatr Dis Treat. 2019; 15:795-808. PMID: 31040679.
      Citations:    
    7. Aaronson ST, Sears P, Ruvuna F, Bunker M, Conway CR, Dougherty DD, Reimherr FW, Schwartz TL, Zajecka JM. A 5-Year Observational Study of Patients With Treatment-Resistant Depression Treated With Vagus Nerve Stimulation or Treatment as Usual: Comparison of Response, Remission, and Suicidality. Am J Psychiatry. 2017 07 01; 174(7):640-648. PMID: 28359201.
      Citations:    
    8. Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RS. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder. Neuropsychopharmacology. 2016 11; 41(12):2961. PMID: 27725683.
      Citations:    
    9. Sanacora G, Johnson MR, Khan A, Atkinson SD, Riesenberg RR, Schronen JP, Burke MA, Zajecka JM, Barra L, Su HL, Posener JA, Bui KH, Quirk MC, Piser TM, Mathew SJ, Pathak S. Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study. Neuropsychopharmacology. 2017 Mar; 42(4):844-853. PMID: 27681442.
      Citations:    
    10. Mischoulon D, Zajecka J, Freeman MP, Fava M. Does folic acid interfere with lamotrigine? Lancet Psychiatry. 2016 08; 3(8):704-705. PMID: 27475760.
      Citations:    
    11. Hollon SD, DeRubeis RJ, Fawcett J, Amsterdam JD, Shelton RC, Zajecka J, Young PR, Gallop R. Notice of Retraction and Replacement. Hollon et al. Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2014;71(10):1157-1164. JAMA Psychiatry. 2016 06 01; 73(6):639-40. PMID: 27097060.
      Citations:    
    12. Zajecka JM, Fava M, Shelton RC, Barrentine LW, Young P, Papakostas GI. Long-term efficacy, safety, and tolerability of L-methylfolate calcium 15 mg as adjunctive therapy with selective serotonin reuptake inhibitors: a 12-month, open-label study following a placebo-controlled acute study. J Clin Psychiatry. 2016 May; 77(5):654-60. PMID: 27035404.
      Citations:    
    13. Shelton RC, Pencina MJ, Barrentine LW, Ruiz JA, Fava M, Zajecka JM, Papakostas GI. Association of obesity and inflammatory marker levels on treatment outcome: results from a double-blind, randomized study of adjunctive L-methylfolate calcium in patients with MDD who are inadequate responders to SSRIs. J Clin Psychiatry. 2015 Dec; 76(12):1635-41. PMID: 26613389.
      Citations:    
    14. Shelton RC, Falola M, Li L, Zajecka J, Fava M, Papakostas GI. The pro-inflammatory profile of depressed patients is (partly) related to obesity. J Psychiatr Res. 2015 Nov; 70:91-7. PMID: 26424427.
      Citations:    
    15. Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RS. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder. Neuropsychopharmacology. 2015 Jul; 40(8):2025-37. PMID: 25687662.
      Citations:    
    16. Hollon SD, DeRubeis RJ, Fawcett J, Amsterdam JD, Shelton RC, Zajecka J, Young PR, Gallop R. Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2014 Oct; 71(10):1157-64. PMID: 25142196.
      Citations:    
    17. Papakostas GI, Shelton RC, Zajecka JM, Bottiglieri T, Roffman J, Cassiello C, Stahl SM, Fava M. Effect of adjunctive L-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotype: results from a randomized clinical trial. J Clin Psychiatry. 2014 Aug; 75(8):855-63. PMID: 24813065.
      Citations:    
    18. Zajecka J, Kornstein SG, Blier P. Residual symptoms in major depressive disorder: prevalence, effects, and management. J Clin Psychiatry. 2013 Apr; 74(4):407-14. PMID: 23656849.
      Citations:    
    19. Zajecka JM. Residual symptoms and relapse: mood, cognitive symptoms, and sleep disturbances. J Clin Psychiatry. 2013; 74 Suppl 2:9-13. PMID: 24191972.
      Citations:    
    20. Papakostas GI, Shelton RC, Zajecka JM, Etemad B, Rickels K, Clain A, Baer L, Dalton ED, Sacco GR, Schoenfeld D, Pencina M, Meisner A, Bottiglieri T, Nelson E, Mischoulon D, Alpert JE, Barbee JG, Zisook S, Fava M. L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry. 2012 Dec; 169(12):1267-74. PMID: 23212058.
      Citations:    
    21. Papakostas GI, Vitolo OV, Ishak WW, Rapaport MH, Zajecka JM, Kinrys G, Mischoulon D, Lipkin SH, Hails KA, Abrams J, Ward SG, Meisner A, Schoenfeld DA, Shelton RC, Winokur A, Okasha MS, Bari MA, Fava M. A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder. J Clin Psychiatry. 2012 Dec; 73(12):1541-7. PMID: 23290327.
      Citations:    
    22. Fava M, Shelton RC, Zajecka JM. Evidence for the use of l-methylfolate combined with antidepressants in MDD. J Clin Psychiatry. 2011 Aug; 72(8):e25. PMID: 21899813.
      Citations:    
    23. DeBattista C, Kinrys G, Hoffman D, Goldstein C, Zajecka J, Kocsis J, Teicher M, Potkin S, Preda A, Multani G, Brandt L, Schiller M, Iosifescu D, Fava M. The use of referenced-EEG (rEEG) in assisting medication selection for the treatment of depression. J Psychiatr Res. 2011 Jan; 45(1):64-75. PMID: 20598710.
      Citations:    
    24. Trivedi MH, Dunner DL, Kornstein SG, Thase ME, Zajecka JM, Rothschild AJ, Friedman ES, Shelton RC, Keller MB, Kocsis JH, Gelenberg A. Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release. J Affect Disord. 2010 Nov; 126(3):420-9. PMID: 20510459.
      Citations:    
    25. Zajecka J, Schatzberg A, Stahl S, Shah A, Caputo A, Post A. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2010 Apr; 30(2):135-44. PMID: 20520286.
      Citations:    
    26. Rothschild AJ, Dunlop BW, Dunner DL, Friedman ES, Gelenberg A, Holland P, Kocsis JH, Kornstein SG, Shelton R, Trivedi MH, Zajecka JM, Goldstein C, Thase ME, Pedersen R, Keller MB. Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) study. Psychopharmacol Bull. 2009; 42(3):5-20. PMID: 19752838.
      Citations:    
    27. Zajecka JM, Gutierrez SN. Oral divalproex sodium loading for adolescent outpatients with acute mania/hypomania: a report of 2 cases. J Clin Psychiatry. 2008 Jun; 69(6):1016-8. PMID: 18683998.
      Citations:    
    28. Keller MB, Trivedi MH, Thase ME, Shelton RC, Kornstein SG, Nemeroff CB, Friedman ES, Gelenberg AJ, Kocsis JH, Dunner DL, Dunlop BW, Hirschfeld RM, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pedersen R, Yan B, Ahmed S, Schmidt M, Ninan PT. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases. Biol Psychiatry. 2007 Dec 15; 62(12):1371-9. PMID: 17825800.
      Citations:    
    29. Keller MB, Trivedi MH, Thase ME, Shelton RC, Kornstein SG, Nemeroff CB, Friedman ES, Gelenberg AJ, Kocsis JH, Dunner DL, Hirschfeld RM, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pedersen RD, Yan B, Ahmed S, Musgnung J, Ninan PT. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases. J Clin Psychiatry. 2007 Aug; 68(8):1246-56. PMID: 17854250.
      Citations:    
    30. Kocsis JH, Thase ME, Trivedi MH, Shelton RC, Kornstein SG, Nemeroff CB, Friedman ES, Gelenberg AJ, Dunner DL, Hirschfeld RM, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pedersen RD, Yan B, Ahmed S, Musgnung J, Ninan PT, Keller MB. Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study. J Clin Psychiatry. 2007 Jul; 68(7):1014-23. PMID: 17685736.
      Citations:    
    31. Raison CL, Woolwine BJ, Demetrashvili MF, Borisov AS, Weinreib R, Staab JP, Zajecka JM, Bruno CJ, Henderson MA, Reinus JF, Evans DL, Asnis GM, Miller AH. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther. 2007 May 15; 25(10):1163-74. PMID: 17451562.
      Citations:    
    32. Blier P, Keller MB, Pollack MH, Thase ME, Zajecka JM, Dunner DL. Preventing recurrent depression: long-term treatment for major depressive disorder. J Clin Psychiatry. 2007 Mar; 68(3):e06. PMID: 17388700.
      Citations:    
    33. Zajecka JM. Augmentation strategies to increase antidepressant tolerability. J Clin Psychiatry. 2007; 68 Suppl 10:23-7. PMID: 17900206.
      Citations:    
    34. Zajecka JM. Calming the bipolar storm: treating acute mania and mixed episodes in patients with bipolar disorder. CNS Spectr. 2006 Nov; 11(11 Suppl 13):1-11; discussion 12-3; quiz 14-6. PMID: 17075560.
      Citations:    
    35. Shelton RC, Haman KL, Rapaport MH, Kiev A, Smith WT, Hirschfeld RM, Lydiard RB, Zajecka JM, Dunner DL. A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder. J Clin Psychiatry. 2006 Nov; 67(11):1674-81. PMID: 17196045.
      Citations:    
    36. Ninan PT, Koran LM, Kiev A, Davidson JR, Rasmussen SA, Zajecka JM, Robinson DG, Crits-Christoph P, Mandel FS, Austin C. High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. J Clin Psychiatry. 2006 Jan; 67(1):15-22. PMID: 16426083.
      Citations:    
    37. Rao D, Zajecka J, Skubiak T. The Modified Rush Sexual Inventory: preliminary psychometric findings. Psychiatry Res. 2005 Dec 15; 137(3):175-81. PMID: 16297981.
      Citations:    
    38. Fava M, Alpert J, Nierenberg AA, Mischoulon D, Otto MW, Zajecka J, Murck H, Rosenbaum JF. A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol. 2005 Oct; 25(5):441-7. PMID: 16160619.
      Citations:    
    39. Rush AJ, Marangell LB, Sackeim HA, George MS, Brannan SK, Davis SM, Howland R, Kling MA, Rittberg BR, Burke WJ, Rapaport MH, Zajecka J, Nierenberg AA, Husain MM, Ginsberg D, Cooke RG. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry. 2005 Sep 01; 58(5):347-54. PMID: 16139580.
      Citations:    
    40. Murck H, Fava M, Alpert J, Nierenberg AA, Mischoulon D, Otto MW, Zajecka J, Mannel M, Rosenbaum JF. Hypericum extract in patients with MDD and reversed vegetative signs: re-analysis from data of a double-blind, randomized trial of hypericum extract, fluoxetine, and placebo. Int J Neuropsychopharmacol. 2005 Jun; 8(2):215-21. PMID: 15458612.
      Citations:    
    41. Zajecka JM, Albano D. SNRIs in the management of acute major depressive disorder. J Clin Psychiatry. 2004; 65 Suppl 17:11-8. PMID: 15600377.
      Citations:    
    42. Gelenberg AJ, Trivedi MH, Rush AJ, Thase ME, Howland R, Klein DN, Kornstein SG, Dunner DL, Markowitz JC, Hirschfeld RM, Keitner GI, Zajecka J, Kocsis JH, Russell JM, Miller I, Manber R, Arnow B, Rothbaum B, Munsaka M, Banks P, Borian FE, Keller MB. Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression. Biol Psychiatry. 2003 Oct 15; 54(8):806-17. PMID: 14550680.
      Citations:    
    43. Tohen M, Ketter TA, Zarate CA, Suppes T, Frye M, Altshuler L, Zajecka J, Schuh LM, Risser RC, Brown E, Baker RW. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry. 2003 Jul; 160(7):1263-71. PMID: 12832240.
      Citations:    
    44. Clayton AH, Zajecka J, Ferguson JM, Filipiak-Reisner JK, Brown MT, Schwartz GE. Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder. Int Clin Psychopharmacol. 2003 May; 18(3):151-6. PMID: 12702894.
      Citations:    
    45. Revicki DA, Paramore LC, Sommerville KW, Swann AC, Zajecka JM. Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes. J Clin Psychiatry. 2003 Mar; 64(3):288-94. PMID: 12716270.
      Citations:    
    46. Zajecka JM. Treating depression to remission. J Clin Psychiatry. 2003; 64 Suppl 15:7-12. PMID: 14658985.
      Citations:    
    47. Zajecka JM, Weisler R, Sachs G, Swann AC, Wozniak P, Sommerville KW. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry. 2002 Dec; 63(12):1148-55. PMID: 12523875.
      Citations:    
    48. Zajecka J, Dunner DL, Gelenberg AJ, Hirschfeld RM, Kornstein SG, Ninan PT, Rush AJ, Thase ME, Trivedi MH, Arnow BA, Borian FE, Manber R, Keller MB. Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination. J Clin Psychiatry. 2002 Aug; 63(8):709-16. PMID: 12197452.
      Citations:    
    49. Ninan PT, Rush AJ, Crits-Christoph P, Kornstein SG, Manber R, Thase ME, Trivedi MH, Rothbaum BO, Zajecka J, Borian FE, Keller MB. Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. J Clin Psychiatry. 2002 May; 63(5):434-41. PMID: 12025827.
      Citations:    
    50. Dunner DL, Laird LK, Zajecka J, Bailey L, Sussman N, Seabolt JL. Six-year perspectives on the safety and tolerability of nefazodone. J Clin Psychiatry. 2002; 63 Suppl 1:32-41. PMID: 11890563.
      Citations:    
    51. Zajecka J, McEnany GW, Lusk KM. Antidepressant dosing and switching guidelines: focus on nefazodone. J Clin Psychiatry. 2002; 63 Suppl 1:42-7. PMID: 11890564.
      Citations:    
    52. Fava M, Dunner DL, Greist JH, Preskorn SH, Trivedi MH, Zajecka J, Cohen M. Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. J Clin Psychiatry. 2001 Jun; 62(6):413-20. PMID: 11465517.
      Citations:    
    53. Zajecka J. Strategies for the treatment of antidepressant-related sexual dysfunction. J Clin Psychiatry. 2001; 62 Suppl 3:35-43. PMID: 11229451.
      Citations:    
    54. Lesem MD, Zajecka JM, Swift RH, Reeves KR, Harrigan EP. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry. 2001 Jan; 62(1):12-8. PMID: 11235922.
      Citations:    
    55. Hirschfeld RM, Williams JB, Spitzer RL, Calabrese JR, Flynn L, Keck PE, Lewis L, McElroy SL, Post RM, Rapport DJ, Russell JM, Sachs GS, Zajecka J. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry. 2000 Nov; 157(11):1873-5. PMID: 11058490.
      Citations:    
    56. Montgomery SA, Schatzberg AF, Guelfi JD, Kasper S, Nemeroff C, Swann A, Zajecka J. Pharmacotherapy of depression and mixed states in bipolar disorder. J Affect Disord. 2000 Sep; 59 Suppl 1:S39-S56. PMID: 11121826.
      Citations:    
    57. Keller MB, McCullough JP, Klein DN, Arnow B, Dunner DL, Gelenberg AJ, Markowitz JC, Nemeroff CB, Russell JM, Thase ME, Trivedi MH, Zajecka J. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med. 2000 May 18; 342(20):1462-70. PMID: 10816183.
      Citations:    
    58. Meaden PM, Daniels RE, Zajecka J. Construct validity of life chart functioning scales for use in naturalistic studies of bipolar disorder. J Psychiatr Res. 2000 May-Jun; 34(3):187-92. PMID: 10867113.
      Citations:    
    59. Hoehn-Saric R, Ninan P, Black DW, Stahl S, Greist JH, Lydiard B, McElroy S, Zajecka J, Chapman D, Clary C, Harrison W. Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders. Arch Gen Psychiatry. 2000 Jan; 57(1):76-82. PMID: 10632236.
      Citations:    
    60. Zajecka JM. Clinical issues in long-term treatment with antidepressants. J Clin Psychiatry. 2000; 61 Suppl 2:20-5. PMID: 10714620.
      Citations:    
    61. Michelson D, Amsterdam JD, Quitkin FM, Reimherr FW, Rosenbaum JF, Zajecka J, Sundell KL, Kim Y, Beasley CM. Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry. 1999 Aug; 156(8):1170-6. PMID: 10450256.
      Citations:    
    62. Zajecka J, Amsterdam JD, Quitkin FM, Reimherr FW, Rosenbaum JF, Tamura RN, Sundell KL, Michelson D, Beasley CM. Changes in adverse events reported by patients during 6 months of fluoxetine therapy. J Clin Psychiatry. 1999 Jun; 60(6):389-94. PMID: 10401918.
      Citations:    
    63. Reimherr FW, Amsterdam JD, Quitkin FM, Rosenbaum JF, Fava M, Zajecka J, Beasley CM, Michelson D, Roback P, Sundell K. Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. Am J Psychiatry. 1998 Sep; 155(9):1247-53. PMID: 9734550.
      Citations:    
    64. Zajecka J, Fawcett J, Amsterdam J, Quitkin F, Reimherr F, Rosenbaum J, Michelson D, Beasley C. Safety of abrupt discontinuation of fluoxetine: a randomized, placebo-controlled study. J Clin Psychopharmacol. 1998 Jun; 18(3):193-7. PMID: 9617977.
      Citations:    
    65. Zajecka JM, Ross JS. A systematized approach to the management of the depressed and anxious patient. Int J Psychiatry Clin Pract. 1998; 2(1):27-30. PMID: 24946243.
      Citations:    
    66. Zajecka J, Tracy KA, Mitchell S. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. J Clin Psychiatry. 1997 Jul; 58(7):291-7. PMID: 9269249.
      Citations:    
    67. Zajecka J, Mitchell S, Fawcett J. Treatment-emergent changes in sexual function with selective serotonin reuptake inhibitors as measured with the Rush Sexual Inventory. Psychopharmacol Bull. 1997; 33(4):755-60. PMID: 9493488.
      Citations:    
    68. Schatzberg AF, Haddad P, Kaplan EM, Lejoyeux M, Rosenbaum JF, Young AH, Zajecka J. Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. Discontinuation Consensus panel. J Clin Psychiatry. 1997; 58 Suppl 7:5-10. PMID: 9219487.
      Citations:    
    69. Schatzberg AF, Haddad P, Kaplan EM, Lejoyeux M, Rosenbaum JF, Young AH, Zajecka J. Possible biological mechanisms of the serotonin reuptake inhibitor discontinuation syndrome. Discontinuation Consensus Panel. J Clin Psychiatry. 1997; 58 Suppl 7:23-7. PMID: 9219490.
      Citations:    
    70. Zajecka J. Importance of establishing the diagnosis of persistent anxiety. J Clin Psychiatry. 1997; 58 Suppl 3:9-13; discussion 14-5. PMID: 9133488.
      Citations:    
    71. Rosenbaum JF, Zajecka J. Clinical management of antidepressant discontinuation. J Clin Psychiatry. 1997; 58 Suppl 7:37-40. PMID: 9219493.
      Citations:    
    72. Zajecka JM. The effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings. J Clin Psychiatry. 1996; 57 Suppl 2:10-4. PMID: 8626357.
      Citations:    
    73. Zajecka JM, Jeffries H, Fawcett J. The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: a retrospective analysis. J Clin Psychiatry. 1995 Aug; 56(8):338-43. PMID: 7635848.
      Citations:    
    74. Nyenhuis DL, Rao SM, Zajecka JM, Luchetta T, Bernardin L, Garron DC. Mood disturbance versus other symptoms of depression in multiple sclerosis. J Int Neuropsychol Soc. 1995 May; 1(3):291-6. PMID: 9375223.
      Citations:    
    75. Zajecka JM, Ross JS. Management of comorbid anxiety and depression. J Clin Psychiatry. 1995; 56 Suppl 2:10-3. PMID: 7844101.
      Citations:    
    76. Schaff MR, Fawcett J, Zajecka JM. Divalproex sodium in the treatment of refractory affective disorders. J Clin Psychiatry. 1993 Oct; 54(10):380-4. PMID: 8262880.
      Citations:    
    77. Zajecka J, Fawcett J. Susceptibility to spontaneous MAOI hypertensive episodes. J Clin Psychiatry. 1991 Dec; 52(12):513-4. PMID: 1752854.
      Citations:    
    78. Fawcett J, Kravitz HM, Zajecka JM, Schaff MR. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. J Clin Psychopharmacol. 1991 Apr; 11(2):127-32. PMID: 2056139.
      Citations:    
    79. Zajecka J, Fawcett J, Schaff M, Jeffriess H, Guy C. The role of serotonin in sexual dysfunction: fluoxetine-associated orgasm dysfunction. J Clin Psychiatry. 1991 Feb; 52(2):66-8. PMID: 1993638.
      Citations:    
    80. Zajecka J, Guy C, Solomon B. Antidepressant drug fever. J Clin Psychopharmacol. 1991 Feb; 11(1):73-4. PMID: 2040721.
      Citations:    
    81. Zajecka JM, Fawcett J. Antidepressant combination and potentiation. Psychiatr Med. 1991; 9(1):55-75. PMID: 2017568.
      Citations:    
    82. Zajecka JM, Fawcett J. Innovative somatic treatments for depression. Psychiatr Med. 1991; 9(1):77-103. PMID: 2017569.
      Citations:    
    83. Zajecka JM, Fawcett J, Guy C. Coexisting major depression and obsessive-compulsive disorder treated with venlafaxine. J Clin Psychopharmacol. 1990 Apr; 10(2):152-3. PMID: 2341595.
      Citations:    
    Zajecka's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (246)
    Explore
    _
    Co-Authors (2)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _